Zydus Lifesciences Ltd. benchmarking: Performance to industry peers

Financial

	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	505.0 .	67.0 .	879.0 .
Number of ANDA's Approved By USFDA	428.0 .	48.0 .	750.0 .
Domestic Sales Growth - YoY	12.0 %	9.8 %	n/a
US DMF Filings	147.0 .	n/a	315.0 .
R&D as a % of Total Sales	8.8 %	2.2 %	4.7 %
Financials
5 yr Average ROE	18.47 %	20.33 %	12.72 %
5yr average Equity Multiplier	1.52	1.46	1.46
5yr Average Asset Turnover Ratio	0.66	0.81	0.68
5yr Avg Net Profit Margin	19.02 %	17.68 %	12.5 %
Price to Book	3.7	6.42	2.47
P/E	18.96	55.16	24.8
5yr Avg Cash Conversion Cycle	-84.89 Days	-13.08 Days	-46.37 Days
Inventory Days	36.38 Days	59.06 Days	59.62 Days
Days Receivable	36.93 Days	34.35 Days	30.33 Days
Days Payable	160.15 Days	121.69 Days	121.28 Days
5yr Average Interest Coverage Ratio	30.19	46.07	43.54
5yr Avg ROCE	19.65 %	25.06 %	15.27 %
5yr Avg Operating Profit Margin	24.4 %	24.62 %	19.22 %
5 yr average Debt to Equity	0.17	0.16	0.19
5yr CAGR Net Profit	16.23 %	9.49 %	-8.16 %
5yr Average Return on Assets	12.22 %	14.46 %	8.64 %
Shareholdings
Promoter Holding	75.0 %	72.66 %	51.82 %
Share Pledged by Promoters	0.0	0.0	23.65 %
Change in Promoter Holding (3 Yrs)	0.02 %	-3.84 %	-0.01 %
Change in Mutual Fund Holding (3 Yrs)	-0.71 %	8.53 %	10.15 %

Business

	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma
Product Wise Break-Up	Product Wise Break-Up US Formulations 41.0 India Formulations 25.0 Wellness 14.0 EMB Formulations 12.0 Active Pharmaceutical Ingredient (API) 3.0 Alliance 0.1 Emerging Markets 0 Europe Formulatios 0 Animal Health 0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 Formulations 0 Others 4.9	Product Wise Break-Up Respiratory 9.0 Active Pharmaceutical Ingredient (API) 0 Cardiovascular 16.0 Emerging Markets 0 Wellness 0 Dermatology 5.0 EMB Formulations 0 Alliance 0 Formulations 0 Gastrointestinal 9.0 India Formulations 0 Anti-infectives 13.0 Gynaecology 10.0 US Formulations 0 Pain/Analgesics 4.0 Europe Formulatios 0 Animal Health 0 Neuro/CNS 2.0 Anti-Diabetic 9.0 VMN 8.0 Urology 5.0 Others 10.0	Product Wise Break-Up Respiratory 0 Active Pharmaceutical Ingredient (API) 0 Cardiovascular 0 Emerging Markets 0 Wellness 0 Dermatology 0 EMB Formulations 0 Alliance 0 Formulations 88.86 Gastro - Intestinal 0 India Formulations 0 Anti-infectives 0 Gynaecology 0 US Formulations 0 Pain/Analgesics 0 Europe Formulatios 0 Animal Health 0 Neuro/CNS 0 Anti-Diabetic 0 VMN 0 Urology 0 Others 11.14
Segment Break-Up	Segment Break-Up Pharmaceuticals 85.95 OTC 14.05	-	-
Location Wise Break-Up	Location Wise Break-Up USA 47.94 India 39.81 Nepal 0 Sri Lanka 0 Bangladesh 0 Europe 0 Rest of the World 0 Others 12.25	Location Wise Break-Up India 85.0 USA 0 Bangladesh 0 Sri Lanka 0 Nepal 0 Rest of the World 0 Europe 0 Others 15.0	Location Wise Break-Up India 9.0 USA 43.2 Bangladesh 0 Sri Lanka 0 Nepal 0 Rest of the World 16.5 Europe 31.3
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 100.0 Consumer Products 0	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Cardiac Science 18.0 Respiratory Systems 14.0 Anti-Infective 12.0 Oncology 9.0 Gastro Intestinal 9.0 Pain Management 8.0 Gynecology 7.0 Dermatology 6.0 Others 17.0	-	-
Asset Break-Up	Asset Break-Up India 93.18 USA 4.31 Europe 0 Others 2.51	-	Asset Break-Up India 65.14 USA 18.21 Europe 7.85 Others 8.8

Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd.

Financial

Business

SIGN UP FOR FREE